SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cambridge Antibody Technology Group -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (428)11/20/2003 7:21:53 PM
From: Madharry  Respond to of 625
 
i added more catg shares here



To: nigel bates who wrote (428)6/9/2004 5:36:01 AM
From: nigel bates  Respond to of 625
 
From the Peptech first half (end 31st March) report; sadly doesn't give any detail on how the Humira payment is made up -

Revenue from ordinary activities has increased from $2.9 million in the previous corresponding half year to $45.5 million in the current period. The increase reflects the one-off payment arising from the settlement of the Abbott dispute plus the first annual payment...


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News